Acid-inhibitory effect of Vonoprazan in erosive oesophagitis patients: a multicenter study via Four-Day Bravo pH Capsule

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100041691

Enrollment

Unknown

Registered

2021-01-01

Start date

2021-02-01

Completion date

Unknown

Last updated

2021-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Reflux esophagitis

Interventions

vonoprazan:Administration of vonoprazan

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 18 and 65 years; 2. Patients with erosive esophagitis diagnosed by endoscopy and had reflux related symptoms (heartburn, acid reflux, retrosternal pain) at least once a week.

Exclusion criteria

Exclusion criteria: 1. Patients who do not want to accept the implantation and monitoring of Bravo capsule. 2. Patients who do not want to receive endoscopy review after 4 weeks of treatment. 3. Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
the percentage of time with esophageal pH less than 4 (%pH<4);	—

Secondary

Measure	Time frame
RDQ score;subject global assessment;Percentage of the successful mucosal healing;	—

Countries

Chinia

Contacts

Public ContactXiaohua Hou

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

houxh@hust.edu.cn+86 13035143646

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026